Beijing Friendship Hospital

Running trials

• Not yet recruiting

  Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

  NCT07835152· Phase 3· Brise Pharmaceuticals Co., Ltd.· Source

• Not yet recruiting

  A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo

  NCT07865312· Phase 3· Dermavon Holdings Limited· Source

• Not yet recruiting

  Clinical Study of YKYY013 Injection in HBeAg-negative Chronic Hepatitis B Virus-infected Patients Treated With Nucleos(t)Ide Analogues

  NCT07933627· Phase 2· Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.· Source

• Not yet recruiting

  Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B

  NCT07589400· Phase 1· Xiamen Amoytop Biotech Co., Ltd.· Source

• Not yet recruiting

  Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer

  NCT07882628· Beijing Chao Yang Hospital· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity

  NCT07845513· Phase 1· Pfizer· Source

• Not yet recruiting

  A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

  NCT07812597· Phase 2· Beijing QL Biopharmaceutical Co.,Ltd· Source

• Recruiting

  A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China

  NCT07900438· Phase 4· Novo Nordisk A/S· Source

• Not yet recruiting

  Phase Ia/Ib Trial of SCTA02A Injection in Healthy Adults and Patients With Chronic Hepatitis B

  NCT07903831· Phase 1· Sinocelltech Ltd.· Source

• Not yet recruiting

  Personalized Intermittent Theta Burst Stimulation for Cognitive Impairment Related to Cerebral Small Vessel Disease

  NCT07891650· Xuanwu Hospital, Beijing· Source

• Recruiting

  Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

  NCT07792681· Phase 2/3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Akeso· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity

  NCT07792954· Phase 3· Pfizer· Source

• Recruiting

  A Study of IBI3046 in Participants With Overweight or Obesity

  NCT07809945· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Recruiting

  Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)

  NCT07767253· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Recruiting

  Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

  NCT07465718· Phase 3· Orphalan· Source

• Recruiting

  Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)

  NCT07718126· Phase 4· West China Hospital· Source

• Not yet recruiting

  HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B

  NCT07780357· Beijing Friendship Hospital· Source

• Recruiting

  Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer

  NCT07835087· Beijing Friendship Hospital· Source

• Recruiting

  A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata

  NCT07733765· Phase 3· Pfizer· Source

• Recruiting

  Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B

  NCT07709520· Phase 2· Fujian Akeylink Biotechnology Co., Ltd.· Source

• Recruiting

  Clinical Study of Coronary Extension Catheter

  NCT07742345· BrosMed Medical Co., Ltd· Source

• Recruiting

  A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis

  NCT07692165· Phase 1/2· Innatus Therapeutics (Shanghai) Co., Ltd.· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· AbbVie· Source

• Recruiting

  A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

  NCT07462143· Phase 2/3· RemeGen Co., Ltd.· Source

• Recruiting

  Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset

  NCT07747688· Beijing Friendship Hospital· Source

• Recruiting

  Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

  NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Recruiting

  A Study of E6742 in Participants With Systemic Lupus Erythematosus

  NCT07515014· Phase 2· Eisai Co., Ltd.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy

  NCT07441850· Beijing Friendship Hospital· Source

• Not yet recruiting

  Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

  NCT07397442· Phase 2· Beijing Friendship Hospital· Source

• Not yet recruiting

  A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

  NCT07483684· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer

  NCT07393048· Beijing Friendship Hospital· Source

• Active, not recruiting

  A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

  NCT07230119· Phase 3· Beijing QL Biopharmaceutical Co.,Ltd· Source

• Recruiting

  JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

  NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Recruiting

  Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

  NCT07262645· Phase 3· Danyang Huichuang Medical Equipment Co., Ltd.· Source

• Recruiting

  Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

  NCT07265570· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  Eye-Brain-Kidney in CKD

  NCT07358572· Beijing Friendship Hospital· Source

• Recruiting

  A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

  NCT07282353· Phase 3· Cascade Pharmaceuticals, Inc· Source

• Recruiting

  A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

  NCT07208058· Phase 3· TJ Biopharma Co., Ltd.· Source

• Recruiting

  Real-world Study of Aflibercept 8 mg in nAMD

  NCT07640997· Peking University People's Hospital· Source

• Recruiting

  Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

  NCT07315854· Phase 2· Beijing Friendship Hospital· Source

• Recruiting

  A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

  NCT07219615· Phase 2· Pfizer· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Not yet recruiting

  Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity

  NCT07135141· Beijing Friendship Hospital· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

Showing 50 of 149.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer13 recruiting
• Gastric and oesophageal cancer13 recruiting
• Fatty liver disease (MASLD/MASH)11 recruiting
• Hepatitis B9 recruiting
• Obesity8 recruiting
• Coronary artery disease6 recruiting
• Lung cancer6 recruiting
• High blood pressure4 recruiting
• Liver cirrhosis4 recruiting
• Pancreatic cancer4 recruiting
• Childhood cancers3 recruiting
• Haemophagocytic lymphohistiocytosis3 recruiting
• Primary biliary cholangitis3 recruiting
• Prostate cancer3 recruiting
• Ulcerative colitis3 recruiting
• Chronic kidney disease2 recruiting
• Head and neck cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Migraine2 recruiting
• Psoriasis2 recruiting
• Type 2 diabetes2 recruiting
• Alopecia areata1 recruiting
• Alzheimer disease1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Cervical cancer1 recruiting
• Chronic spontaneous urticaria1 recruiting
• Crohn's disease1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Endometrial cancer1 recruiting
• Haemophilia1 recruiting
• Heart failure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lupus (SLE)1 recruiting
• Macular degeneration1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 1 diabetes1 recruiting
• Vascular dementia1 recruiting
• Vitiligo1 recruiting
• Wilson disease1 recruiting

Closed trials

• Completed

  Rejection After Auxiliary Partial Orthotopic Liver Transplantation: An Exploratory Comparison by Native-Liver Cirrhosis Status

  NCT07275008· Zhi-Jun Zhu· Source

• Terminated

  A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

  NCT07100938· Phase 2· BeiGene· Source

• Completed

  HPP737 in Adult Patients With Plaque Psoriasis

  NCT07712731· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Recruiting

  Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06842199· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Completed

  Safety, Tolerability, and Pharmacokinetics of a Single or Multiple Ascending Doses of CPX101

  NCT06545162· Phase 1· Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.· Source

• Completed

  Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women

  NCT06682663· Peking University· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Completed

  Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites

  NCT06553456· Phase 2/3· Beijing Protgen Biotechnology Development Co., Ltd.· Source

• Completed

  Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

  NCT06550128· Phase 2· Ausper Biopharma Co., Ltd.· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Bayer· Source

• Completed

  A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients

  NCT06732960· Phase 2· Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.· Source

• Completed

  Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06477237· Phase 3· Huabo Biopharm Co., Ltd.· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

  NCT06269107· Phase 3· Novo Nordisk A/S· Source

• Completed

  The Safety and Efficiency of Stent-based Diverting Technique Versus Ileostomy in Rectal Cancer Patients

  NCT06204497· Sir Run Run Shaw Hospital· Source

• Completed

  Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

  NCT06228560· Phase 2· Longbio Pharma· Source

• Completed

  A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects

  NCT07529600· Phase 1· Arnatar Therapeutics, Inc.· Source

• Completed

  Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

  NCT06109818· Phase 2· Beijing InnoCare Pharma Tech Co., Ltd.· Source

• Terminated

  A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

  NCT06082843· Phase 2· Boehringer Ingelheim· Source

• Withdrawn

  Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia

  NCT06176235· Phase 2· Peking University People's Hospital· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Pfizer· Source

• Completed

  Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06353347· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis

  NCT06109805· Beijing Friendship Hospital· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

  NCT06024356· Beijing Friendship Hospital· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

  NCT05775705· Beijing Friendship Hospital· Source

• Completed

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05938920· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Completed

  Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

  NCT05890976· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05507580· Phase 4· AbbVie· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

  NCT07712705· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease

  NCT05811442· Phase 2· Beijing Joekai Biotechnology LLC· Source

• Completed

  Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

  NCT05949801· Phase 3· Zensun Sci. & Tech. Co., Ltd.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia

  NCT06355479· Phase 3· Healthgen Biotechnology Corp.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

  NCT07034209· Phase 2· TJ Biopharma Co., Ltd.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

  NCT06066125· Phase 3· Akeso· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Completed

  This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

  NCT06746311· Phase 1· Suzhou HepaThera Biotech Co., Ltd.· Source

• Completed

  Comparison of Three Different Puncture Techniques in EBUS-TBNA

  NCT05628454· Beijing Friendship Hospital· Source

• Completed

  The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

  NCT05438875· Phase 3· Peking University People's Hospital· Source

• Terminated

  Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

  NCT05461794· Phase 2· BeiGene· Source

• Terminated

  Efficacy and Safety of Wei Li Bai Capsules in the Treatment of Alzheimer's Disease

  NCT05670912· Phase 2· Capital Medical University· Source

• Completed

  A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

  NCT05174221· Phase 1· Takeda· Source

• Completed

  A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

  NCT05734807· Phase 2· Huahui Health· Source

• Terminated

  A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

  NCT05282121· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Amgen· Source

• Completed

  A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

  NCT05371652· Phase 3· Pfizer· Source

Showing 50 of 82.

Conditions

Diseases this institution publishes on or runs trials for.

• Gastric and oesophageal cancer50 works · 21 trials
• Fatty liver disease (MASLD/MASH)38 works · 15 trials
• Neuroblastoma36 works · 0 trials
• Hearing loss21 works · 0 trials
• Hepatitis B15 works · 14 trials
• Haemophagocytic lymphohistiocytosis12 works · 6 trials
• Irritable bowel syndrome8 works · 0 trials
• Brain aneurysm7 works · 0 trials
• Liver cirrhosis7 works · 11 trials
• Primary biliary cholangitis5 works · 7 trials
• Wilson disease4 works · 1 trial